RxDoctor Payments Data

Francis Williams, MD

Rheumatology · San Antonio, TXNPI 1275519449

Payments from drug & device makers

$31,410in general payments, 2019–2025

Across 97 payments — averaging $323.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$27K
  • AbbVie$2K
  • Bristol Myers Squibb$2K
  • UCB, Inc.$215
  • AstraZeneca$125
  • Mallinckrodt Enterprises LLC$124
  • plus $87 from 1 others

What the payments were for

  • Consulting fees$1,8236%
  • Speaking & faculty fees$22,43871%
  • Travel & lodging$2,6188%
  • Food & beverage$4,52414%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)56$26,581
AbbVie34$2,347
Bristol Myers Squibb2$1,930
UCB, Inc.2$215
AstraZeneca1$125
Mallinckrodt Enterprises LLC1$124
Pfizer1$87

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,410 in reported general payments places this provider in the 70th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$9,109
Medicare patients
49
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab208$1,562,071
Enbrel SureclickEtanercept140$1,148,438
RinvoqUpadacitinib58$415,707
Orencia ClickjectAbatacept55$343,675
Xeljanz XrTofacitinib Citrate35$213,085
Cimzia (2 Pack)Certolizumab Pegol25$210,773
OrenciaAbatacept30$198,313
Cosentyx Sensoready (2 Pens)Secukinumab24$192,594
OtezlaApremilast28$158,273
Cosentyx Sensoready PenSecukinumab18$154,347
EnbrelEtanercept11$81,036
Actemra ActpenTocilizumab14$65,489
ProliaDenosumab20$36,787
Teriparatide12$17,949
RidauraAuranofin15$13,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,347$415,70758 claims
AmgenOtezla, Enbrel, Prolia$26,581$276,09659 claims
UCB, Inc.Cimzia (2 Pack)$215$210,77325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 512 rheumatology providers in Texas.

Other rheumatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →